Nested Therapeutics
Nested Therapeutics is a precision oncology company focused on discovering and developing small-molecule drugs that target overlooked driver mutations in cancer. Utilizing a unique drug discovery platform that integrates genomics, computational biophysics, and machine learning, Nested aims to create therapeutics that can address the vast array of cancer-associated mutations. Their lead program, NST-628, is a novel molecular glue targeting the RAS/MAPK pathway, demonstrating superior efficacy in preclinical models. With a team of industry pioneers and a commitment to innovation, Nested Therapeutics is positioned to make significant advancements in the field of precision medicine, aiming to deliver one investigational new drug (IND) per year.
Nested Therapeutics
Nested Therapeutics is a precision oncology company focused on discovering and developing small-molecule drugs that target overlooked driver mutations in cancer. Utilizing a unique drug discovery platform that integrates genomics, computational biophysics, and machine learning, Nested aims to create therapeutics that can address the vast array of cancer-associated mutations. Their lead program, NST-628, is a novel molecular glue targeting the RAS/MAPK pathway, demonstrating superior efficacy in preclinical models. With a team of industry pioneers and a commitment to innovation, Nested Therapeutics is positioned to make significant advancements in the field of precision medicine, aiming to deliver one investigational new drug (IND) per year.
TL;DR
Founded: 2021
Headquarters: Cambridge, Massachusetts
Therapeutic focus: Precision oncology — mutation‑selective small molecules
Lead program: NST-628 (brain‑penetrant pan‑RAF/MEK molecular glue, Phase 1)
Total funding: USD 125,000,000
Company Overview
Problem Domain
Cancer — mutation‑defined/cryptic pockets for targeted small‑molecule therapeutics
Founded
2021
Industry
Biotechnology
Funding Track Record
Early/founder funding tied to Versant Ventures
USD 90,000,000
Series A led by Goldman Sachs Asset Management as part of $125M total financing announced at launch
Investor Signal
“Includes participation from Foresite Capital, Avidity Partners, Cowen Healthcare Investments and Section 32”